310
Views
7
CrossRef citations to date
0
Altmetric
Review Articles

An updated review of mesoporous carbon as a novel drug delivery system

ORCID Icon, , , , , , & ORCID Icon show all
Pages 1029-1037 | Received 09 Nov 2020, Accepted 13 Jun 2021, Published online: 11 Oct 2021
 

Abstract

The nanotechnology approach has been recently adopted to provide more reliable, effective, controlled, and safe drug delivery systems. Nanostructured materials have gained great interest, including siliceous and carbonaceous nanoparticles. The effectiveness of mesoporous carbon nanoparticles (MCNs) in tumor imaging, targeting, and treatment is urging for more future studies. MCNs possess superior properties such as their biocompatibility, large surface area, large pore volume, tunability, and more responsive behavior to internal and external release triggers. These outstanding features make MCNs more applicable for stimuli-responsive drug delivery than the conventional forms of mesoporous silica nanoparticles (MSNs) and other carbon nanoparticles. In this review, we outlined the latest updates regarding the safety, benefits, and potential applications of MCNs.

Acknowledgments

The authors want to expand their sincere thanks to Prof.Dr./ Fakhr El-Din Soliman Ghazy (Dept. of pharmaceutics, Zagazig University), Alaa M. Radwan (Dept. of Pharmaceutical sciences, University of Colorado) for their support.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.